Opinion|Videos|September 18, 2024
Evaluating Imaging Agents in Oligometastatic Prostate Cancer: A Comparative Analysis of Gallium-Based and Non-Gallium-Based Options
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- Can you discuss the advantages and limitations of different imaging agents commonly used in identifying oligometastatic disease in prostate cancer, such as gallium-based agents versus non-gallium-based agents?
- Are you aware of any differences in lesion detection rates or staging accuracy between gallium vs non- gallium-based PET imaging agents?
Advertisement
Related to this article
In addition to providing higher SNRs in vascular structures and parenchymal organs than energy-integrating detector CT, photon-counting CT enabled an approximately 30 percent reduction in volume CT dose index (CTDIvol) for patients with obesity, according to a new study.
Facilitating enhanced 3D visualization of skeletal anatomy, the BoneEnhance machine learning module reportedly provides automated segmentation of bone and surrounding tissues for the Accuro XV ultrasound system.
Newly published preclinical research signals a substantial conceptual shift with a potential role of photon-counting CT in targeting specific biological processes.
The future of AI in radiology lies in its potential capability to forge connections and enhance efficiencies for enterprise-wide workflows.
In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Could Photon-Counting CT Have an Impact as a Platform for Molecular Imaging?
2
FDA Clears Machine Learning Module for Emerging Musculoskeletal Ultrasound Platform
3
What’s Next for AI in Radiology?: Facilitating Data Orchestration Over Fragmentation
4
Can the Kaiser Score with Breast MRI Improve Clarity for BI-RADS 0 and 4 Assessments on Mammography and Ultrasound?
5